Santen Pharmaceutical Co., Ltd.

4536

JP3336000009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:00:00 24/05/2024 BST			5-day change	1st Jan Change
1,550 ^JPY	+0.78%		-2.97%	+10.36%

05-10	Santen Pharmaceutical Intends to Buy Back and Cancel up to 38 Billion Yen Worth of Shares	MT
05-09	Santen Pharmaceutical Co., Ltd. announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.	CI

Santen Pharmaceutical Co., Ltd. authorizes a Buyback Plan.

May 08, 2024

The Board of Directors of Santen Pharmaceutical Co., Ltd. has authorized a buyback plan on May 9, 2024.

Latest news about Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical Intends to Buy Back and Cancel up to 38 Billion Yen Worth of Shares	05-10	MT
Santen Pharmaceutical Co., Ltd. announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.	05-09	CI
Santen Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Full Year Ending March 31, 2025	05-09	CI
Santen Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2024, Payable on June 26, 2024; Provides Dividend Guidance for the End of Second Quarter of 2025	05-09	CI
Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2025	05-09	CI
Santen Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	05-08	CI
Santen Pharmaceutical to Cancel 12 Million Treasury Shares	03-26	MT
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024	03-25	CI
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	03-25	CI
Santen Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2023, has closed with 12,571,400 shares, representing 3.38% for ¥16,178.35 million.	03-21	CI
Santen Pharmaceutical's Returns to the Black in Fiscal Nine Months	02-09	MT
Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024	02-08	CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,700 Yen From 1,650 Yen, Keeps at Buy	01-29	MT
Santen Pharmaceutical Further Repurchases Shares for Over 1 Billion Yen	01-08	MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	01-05	CI
Santen Pharmaceutical Buys Back Nearly 2 Billion Yen of Shares	12-04	MT
Santen Pharmaceutical’s Fiscal H1 EPS Increases to 69.68 Yen as Net Sales Rise 13.1% to 145.81 Billion Yen; Declares Interim Dividend of 16 Yen Per Share, Maintains Forecast	11-08	MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	11-07	CI
Santen Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on November 30, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	11-07	CI
Santen Pharmaceutical Buys Back 523,400 shares for 772.6 Million Yen in September	03/10/23	MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	02/10/23	CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,650 Yen From 1,400 Yen, Keeps at Buy	21/09/23	MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	20/09/23	CI
Santen Pharmaceutical Co., Ltd. Provides Dividend Forecasts for Second Quarter of 2024 and the Fiscal Year Ending March 31, 2024	03/08/23	CI
Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	03/08/23	CI

Chart Santen Pharmaceutical Co., Ltd.

Duration

Period

More charts

SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.

Sector

Pharmaceuticals

Calendar

24/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Santen Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,538 JPY

Average target price

1,787 JPY

Spread / Average Target

+16.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANTEN PHARMACEUTICAL CO., LTD.	+10.36%	3.56B
ELI LILLY AND COMPANY	+38.69%	728B
NOVO NORDISK A/S	+33.81%	603B
JOHNSON & JOHNSON	-4.49%	360B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	279B
ASTRAZENECA PLC	+16.06%	244B
NOVARTIS AG	+7.82%	207B
ROCHE HOLDING AG	-5.48%	205B
PFIZER, INC.	-0.35%	163B

Other Pharmaceuticals